The NYSE American will review the compliance plan and may grant up to 18 months for the company to regain compliance. Failure to do so could result in delisting, which would severely impact liquidity and access to capital. Monitor for the exchange's decision and any subsequent equity-raising actions.
Price Chart
Executive Summary
Actinium Pharmaceuticals filed an 8-K on June 18, 2026, disclosing that it submitted a compliance plan to NYSE American after receiving a notice on May 27, 2026, that it failed to meet the continued listing standard requiring at least $4.0 million in stockholders' equity. The company had reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
Key Facts
- On May 27, 2026, Actinium received a notice from NYSE American that it was not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide, which requires a listed company to maintain stockholders' equity of $4.0 million or more if it reported losses in three of its four most recent fiscal years.
- On June 18, 2026, the company submitted a compliance plan to NYSE American outlining actions management intends to take to restore compliance with applicable listing standards.
- The company has a market cap of $32 million and is a micro-cap biotech with no disclosed revenue in the filing.
Financial Impact
The company faces potential delisting from NYSE American if its compliance plan is not accepted. The minimum equity threshold is $4.0 million; the company's current equity level is not disclosed in this filing.
Risk Factors
- Potential delisting from NYSE American if compliance plan is not accepted or if the company fails to regain compliance within the cure period.
- Micro-cap biotech with no disclosed revenue and a history of losses faces ongoing viability risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-070193 |
| Document: 0001213900-26-070193-index-headers.html | 0001213900-26-070193 |
| Document: 0001213900-26-070193-index.html | 0001213900-26-070193 |
| Document: 0001213900-26-070193.txt | 0001213900-26-070193 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | DEF 14A | $1.13 | awaiting T+20 | — | $1.40 (+23.89%) |
Oct 15, 2026 11d ago | 8-K | $1.13 | awaiting T+20 | — | $1.40 (+23.89%) |
Aug 14, 2026 10w ago | Press Release | $1.05 $1.25 | ▲ +19.05% | ▲ +21.03% | $1.40 (+33.33%) |
Aug 14, 2026 10w ago | 8-K | $1.05 $1.25 | ▼ −19.05% | ▼ −21.03% | $1.40 (−33.33%) |
Jun 18, 2026 18w ago | 8-K | $1.03 $0.9219 | ▲ +10.50% | ▲ +10.35% | $1.40 (−35.92%) |
May 29, 2026 21w ago | 8-K | $1.18 $0.9800 | ▲ +16.95% | ▲ +15.65% | $1.40 (−18.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers